Possible new treatment for MS on the horizonPublished: 30 May 2021 A new less expensive, more convenient treatment for multiple sclerosis (MS) could be on the horizon. Ublituximad, made by TG Therapeutics, has been shown to significantly reduce the annualised relapse rate in people with relapsing MS when compared with teriflunomide in a recent phase three trial. Ublituximad is a glycoengineered anti-CD20 monoclonal antibody – glycoengineering means scientists changed protein-associated carbohydrates which alters its pharmacokinetic properties. If the US Food and Drug Administration approve the drug, it will be the only glycoengineered anti-CD20 monoclonal antibody for MS. There are other anti-CD20 drugs for MS but they need four-hour-long infusions, which can be inconvenient. Ublituximad needs much less time. The findings were presented at the virtual Congress of the European Academy of Neurology 2021. Other Stories You May Be Interested In... News Antibodies detected in blood of 10% of MS patients years before diagnosis View article News Stroke risk higher in people with MS, study finds View article News Subcutaneous Ocrevus shows almost complete suppression of relapses View article